vs
Side-by-side financial comparison of CALERES INC (CAL) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
CALERES INC is the larger business by last-quarter revenue ($790.1M vs $708.5M, roughly 1.1× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 0.3%, a 18.8% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 6.6%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-12.4M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 6.5%).
Caleres Inc. is an American footwear company that owns and operates a variety of footwear brands. Its headquarters is located in Clayton, Missouri, a suburb of St. Louis. The company was founded in 1878 as Bryan, Brown & Company in St. Louis, though it underwent several name changes. The Hamilton-Brown Shoe Company was the largest manufacturer of shoes in America in the early 20th century, but it went bankrupt in June 1939.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
CAL vs MEDP — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $790.1M | $708.5M |
| Net Profit | $2.4M | $135.1M |
| Gross Margin | 41.8% | — |
| Operating Margin | 1.5% | 21.6% |
| Net Margin | 0.3% | 19.1% |
| Revenue YoY | 6.6% | 32.0% |
| Net Profit YoY | -94.2% | 15.5% |
| EPS (diluted) | $0.07 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $790.1M | $708.5M | ||
| Q3 25 | $658.5M | $659.9M | ||
| Q2 25 | $614.2M | $603.3M | ||
| Q1 25 | $639.2M | $558.6M | ||
| Q4 24 | $740.9M | $536.6M | ||
| Q3 24 | $683.3M | $533.3M | ||
| Q2 24 | $659.2M | $528.1M | ||
| Q1 24 | $697.1M | $511.0M |
| Q4 25 | $2.4M | $135.1M | ||
| Q3 25 | $6.7M | $111.1M | ||
| Q2 25 | $6.9M | $90.3M | ||
| Q1 25 | $4.9M | $114.6M | ||
| Q4 24 | $41.4M | $117.0M | ||
| Q3 24 | $30.0M | $96.4M | ||
| Q2 24 | $30.9M | $88.4M | ||
| Q1 24 | $55.7M | $102.6M |
| Q4 25 | 41.8% | — | ||
| Q3 25 | 43.4% | — | ||
| Q2 25 | 45.4% | — | ||
| Q1 25 | 43.0% | — | ||
| Q4 24 | 44.1% | — | ||
| Q3 24 | 45.5% | — | ||
| Q2 24 | 46.9% | — | ||
| Q1 24 | 43.9% | — |
| Q4 25 | 1.5% | 21.6% | ||
| Q3 25 | 1.4% | 21.5% | ||
| Q2 25 | 1.9% | 20.9% | ||
| Q1 25 | 1.2% | 20.3% | ||
| Q4 24 | 7.7% | 23.4% | ||
| Q3 24 | 6.2% | 21.1% | ||
| Q2 24 | 6.5% | 19.9% | ||
| Q1 24 | 4.4% | 20.4% |
| Q4 25 | 0.3% | 19.1% | ||
| Q3 25 | 1.0% | 16.8% | ||
| Q2 25 | 1.1% | 15.0% | ||
| Q1 25 | 0.8% | 20.5% | ||
| Q4 24 | 5.6% | 21.8% | ||
| Q3 24 | 4.4% | 18.1% | ||
| Q2 24 | 4.7% | 16.7% | ||
| Q1 24 | 8.0% | 20.1% |
| Q4 25 | $0.07 | $4.65 | ||
| Q3 25 | $0.20 | $3.86 | ||
| Q2 25 | $0.21 | $3.10 | ||
| Q1 25 | $0.17 | $3.67 | ||
| Q4 24 | $1.19 | $3.67 | ||
| Q3 24 | $0.85 | $3.01 | ||
| Q2 24 | $0.88 | $2.75 | ||
| Q1 24 | $1.56 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.0M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $616.8M | $459.1M |
| Total Assets | $2.1B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.0M | $497.0M | ||
| Q3 25 | $191.5M | $285.4M | ||
| Q2 25 | $33.1M | $46.3M | ||
| Q1 25 | $29.6M | $441.4M | ||
| Q4 24 | $33.7M | $669.4M | ||
| Q3 24 | $51.8M | $656.9M | ||
| Q2 24 | $30.7M | $510.9M | ||
| Q1 24 | $21.4M | $407.0M |
| Q4 25 | $616.8M | $459.1M | ||
| Q3 25 | $613.3M | $293.6M | ||
| Q2 25 | $605.2M | $172.4M | ||
| Q1 25 | $599.0M | $593.6M | ||
| Q4 24 | $598.3M | $825.5M | ||
| Q3 24 | $606.1M | $881.4M | ||
| Q2 24 | $570.3M | $763.6M | ||
| Q1 24 | $560.6M | $671.5M |
| Q4 25 | $2.1B | $2.0B | ||
| Q3 25 | $2.2B | $1.8B | ||
| Q2 25 | $1.9B | $1.6B | ||
| Q1 25 | $1.9B | $1.9B | ||
| Q4 24 | $2.0B | $2.1B | ||
| Q3 24 | $2.0B | $2.1B | ||
| Q2 24 | $1.9B | $1.9B | ||
| Q1 24 | $1.8B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.2M | $192.7M |
| Free Cash FlowOCF − Capex | $-12.4M | $188.1M |
| FCF MarginFCF / Revenue | -1.6% | 26.6% |
| Capex IntensityCapex / Revenue | 1.4% | 0.6% |
| Cash ConversionOCF / Net Profit | -0.50× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $14.4M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.2M | $192.7M | ||
| Q3 25 | $47.3M | $246.2M | ||
| Q2 25 | $-5.7M | $148.5M | ||
| Q1 25 | $28.7M | $125.8M | ||
| Q4 24 | $-39.8M | $190.7M | ||
| Q3 24 | $79.6M | $149.1M | ||
| Q2 24 | $36.1M | $116.4M | ||
| Q1 24 | $43.0M | $152.7M |
| Q4 25 | $-12.4M | $188.1M | ||
| Q3 25 | $35.0M | $235.5M | ||
| Q2 25 | $-26.2M | $142.4M | ||
| Q1 25 | $18.0M | $115.8M | ||
| Q4 24 | $-57.4M | $183.0M | ||
| Q3 24 | $68.5M | $138.5M | ||
| Q2 24 | $26.3M | $103.5M | ||
| Q1 24 | $32.4M | $147.2M |
| Q4 25 | -1.6% | 26.6% | ||
| Q3 25 | 5.3% | 35.7% | ||
| Q2 25 | -4.3% | 23.6% | ||
| Q1 25 | 2.8% | 20.7% | ||
| Q4 24 | -7.7% | 34.1% | ||
| Q3 24 | 10.0% | 26.0% | ||
| Q2 24 | 4.0% | 19.6% | ||
| Q1 24 | 4.6% | 28.8% |
| Q4 25 | 1.4% | 0.6% | ||
| Q3 25 | 1.9% | 1.6% | ||
| Q2 25 | 3.3% | 1.0% | ||
| Q1 25 | 1.7% | 1.8% | ||
| Q4 24 | 2.4% | 1.4% | ||
| Q3 24 | 1.6% | 2.0% | ||
| Q2 24 | 1.5% | 2.4% | ||
| Q1 24 | 1.5% | 1.1% |
| Q4 25 | -0.50× | 1.43× | ||
| Q3 25 | 7.05× | 2.22× | ||
| Q2 25 | -0.81× | 1.65× | ||
| Q1 25 | 5.82× | 1.10× | ||
| Q4 24 | -0.96× | 1.63× | ||
| Q3 24 | 2.66× | 1.55× | ||
| Q2 24 | 1.17× | 1.32× | ||
| Q1 24 | 0.77× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CAL
| Brand Portfolio | $383.7M | 49% |
| Landed Wholesale | $148.1M | 19% |
| Wholesale E Commerce | $75.0M | 9% |
| Ecommerce | $68.8M | 9% |
| Stuart Weitzman Brand | $45.8M | 6% |
| Landed Wholesale Ecommerce Drop Ship | $30.6M | 4% |
| First Cost Wholesale | $14.9M | 2% |
| Clt Brand Solutions | $10.2M | 1% |
| License And Royalty | $2.1M | 0% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
